Use of anticoagulation in thyroid disease

James L Polmear, Matthew J.L. Hare, Sarah R Catford, Duncan J Topliss, Michael J Dooley

Research output: Contribution to journalArticlepeer-review


Background Hyperthyroidism and atrial fibrillation (AF) are both common in the Australian community, and often encountered in general practice.

Objective This article discusses the risk of AF and thromboembolism in hyperthyroidism, the role of antithrombotic therapy in this setting, and appropriateness and safety of various antithrombotic agents in thyroid disease. 
Discussion Prevention of thromboembolism is an important consideration in the care of patients with AF and hyperthyroidism. However, the evaluation of thromboembolic risk and management in this setting is challenging. Thyroid disease results in a pro-coagulant state via disruption of coagulation pathways and alters the pharmacodynamics of anticoagulants. Currently, guidelines regarding anticoagulation in AF do not incorporate hyperthyroidism as an additional risk factor. Until further evidence becomes available, we recommend warfarin as the oral anticoagulant of choice in thyroid disease because of ease of monitoring and reversibility.
Original languageEnglish
Pages (from-to)109-111
Number of pages3
JournalAustralian Journal for General Practitioners
Issue number3
Publication statusPublished - Mar 2016
Externally publishedYes


Dive into the research topics of 'Use of anticoagulation in thyroid disease'. Together they form a unique fingerprint.

Cite this